Choi Chul Won, Cho Chul Koo, Yoo Seong Yul, Kim Mi Sook, Yang Kwang Mo, Yoo Hyung Jun, Seo Young Seok, Kang Jin Kyu, Lee Dong Han, Lee Kyung Hee, Lee Eui Don, Rhu Sang Young, Choi Suck Chul, Kim Moon Hong, Kim Beob Jong
Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, Korea.
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):147-53. doi: 10.1016/j.ijrobp.2008.07.020. Epub 2008 Nov 5.
The aims of this study were to evaluate the role of stereotactic body radiation therapy (SBRT) as a local treatment for isolated para-aortic lymph node (PALN) metastases originating from uterine cervical and corpus cancer.
We retrospectively enrolled 30 patients with isolated PALN metastases originating from uterine cervical and corpus cancer who had received SBRT using the CyberKnife (CK). All patients were shown to have isolated PALN metastases by computed tomography (CT) and/or positron emission tomography (PET)-CT. The overall survival (OS), local control (LC) rate, and disease progression-free survival (DPFS) rate were calculated according to the Kaplan-Meier method. Comparison between prognosis groups was performed using log-rank analysis. Toxicities were also evaluated.
The 4-year OS rate was 50.1%, and the median survival time was not reached. The OS rate among symptomatic patients was significantly lower than that among asymptomatic patients (p = 0.002). The 4-year actuarial LC rate was 67.4%. Patients with a planning target volume of </=17 ml had significantly higher LC rates (p = 0.009). The 4-year DPFS rate was 45.0%, and the median time to disease progression was 32 months. Small planning target volume was a favorable prognostic factor (p = 0.043). Grade 3 or 4 complications requiring hospitalization were reported in 1 patient at 20 months after SBRT.
The OS and LS rates were promising, and the incidence of toxicities was low. Use of SBRT with the CyberKnife is an effective modality for treating isolated PALN metastases in patients with uterine cervical and corpus cancer.
本研究旨在评估立体定向体部放射治疗(SBRT)作为子宫颈癌和子宫体癌孤立性主动脉旁淋巴结(PALN)转移的局部治疗方法的作用。
我们回顾性纳入了30例子宫颈癌和子宫体癌孤立性PALN转移且使用射波刀(CK)接受SBRT治疗的患者。所有患者均经计算机断层扫描(CT)和/或正电子发射断层扫描(PET)-CT证实为孤立性PALN转移。根据Kaplan-Meier方法计算总生存期(OS)、局部控制(LC)率和无疾病进展生存期(DPFS)率。使用对数秩检验分析预后组之间的差异。同时评估毒性反应。
4年OS率为50.1%,中位生存时间未达到。有症状患者的OS率显著低于无症状患者(p = 0.002)。4年精算LC率为67.4%。计划靶体积≤17 ml的患者LC率显著更高(p = 0.009)。4年DPFS率为45.0%,疾病进展的中位时间为32个月。小计划靶体积是一个有利的预后因素(p = 0.043)。1例患者在SBRT后20个月出现3级或4级需要住院治疗的并发症。
OS和LC率前景良好,毒性反应发生率低。使用射波刀进行SBRT是治疗子宫颈癌和子宫体癌患者孤立性PALN转移的有效方式。